Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akeso Pharmaceuticals

www.akeso.ru

Latest From Akeso Pharmaceuticals

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

China Clinical Trials

After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China

Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.

China Research & Development

Finance Watch: Cell And Gene Therapies Buck 2019’s Venture Capital Trend

Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.

Financing Regenerative Medicine

China's Akeso Bets On IO Antibody Combo With First US IND

Emerging Company Profile: Akeso's lead compound is the bispecific antibody AK104, which targets the checkpoints PD-1 and CTLA-4. It will be advanced globally with a first indication in gastric and gastroesophageal junction cancers. This is the first in a series of China-based emerging company profiles.

ImmunoOncology Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Russia
  • Parent & Subsidiaries
  • Akeso Pharmaceuticals
  • Senior Management
  • Kristina Rudolf, Head, Bus. Dev.
    Julia Arhipova, Head, Fin.
    Imran Mir, Managing Dir.
    Alexandr Medvedev, Head, Sales
  • Contact Info
  • Akeso Pharmaceuticals
    Phone: 812 490 76 60
    Irinovsky Ave., 1, Lit. 2
    St. Petersburg, 195248
    Russia
UsernamePublicRestriction

Register